Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ovid Therapeutics Inc.

1.60
-0.0300-1.84%
Volume:1.32M
Turnover:2.18M
Market Cap:113.78M
PE:-2.99
High:1.73
Open:1.65
Low:1.60
Close:1.63
52wk High:2.01
52wk Low:0.2425
Shares:71.11M
Float Shares:59.52M
Volume Ratio:1.01
T/O Rate:2.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5359
EPS(LYR):-0.3663
ROE:-52.77%
ROA:-26.71%
PB:2.04
PE(LYR):-4.37

Loading ...

Ovid Therapeutics Q2 2025: Revenues Surge to $6.3M, Net Loss of $4.7M, EPS at -$0.06

Reuters
·
Aug 13

BRIEF-Ovid Therapeutics Q2 Revenue USD 6.272 Million Vs. IBES Estimate USD 76.7 Thousand

Reuters
·
Aug 13

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

THOMSON REUTERS
·
Aug 13

Ovid Therapeutics Q2 Operating Expenses USD 11.345 Million

THOMSON REUTERS
·
Aug 13

Ovid Therapeutics Inc - Has $38.3 Mln Cash to Support Operations Into Early 2H 2026

THOMSON REUTERS
·
Aug 13

Ovid Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
Aug 09

Ovid Therapeutics Inc. to Participate in BTIG Virtual Biotech Conference

Reuters
·
Jul 23

Ovid Therapeutics Inc. Conducted Annual Stockholder Meeting

Reuters
·
Jul 11

Ovid Therapeutics Sells Future Ganaxolone Royalties to Immedica Pharma for $7 Million

Reuters
·
Jun 25

Ovid Therapeutics Inc. Unveils Corporate Presentation Highlighting Precision Small Molecule Programs and Differentiated Pipeline for Neurological Disorders

Reuters
·
Jun 13

Ovid Therapeutics Inc. to Host Investor and Media Event on Emerging Epilepsy Biomarkers and OV329 Program Highlights

Reuters
·
Jun 05

Ovid Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Ovid Therapeutics Q1 EPS $(0.14), Inline, Sales $130.00K Beat $50.00K Estimate

Benzinga
·
May 13

BRIEF-Ovid Therapeutics Q1 Operating Expenses USD 12.68 Million

Reuters
·
May 13

Ovid Therapeutics Reports Q1 2025 Net Loss of $10.2M, EPS Improves to $0.14 as Revenues Slip to $130K

Reuters
·
May 13

Press Release: Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Dow Jones
·
May 13

Ovid Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
May 09